Benefits
Total testosterone increase meta-analysis (Leisegang 2022 PMID 36013514)
Leisegang K, Finelli R, Sikka SC, Panner Selvam MK 2022 (PMID 36013514, Medicina 58(8):1047, doi:10.3390/medicina58081047) — SYSTEMATIC REVIEW + META-ANALYSIS of E. longifolia clinical trials. PRISMA guidelines. 9 studies in systematic review; 5 RCTs in meta-analysis. RESULTS: SIGNIFICANT INCREASE in TOTAL TESTOSTERONE (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect CONFIRMED in HYPOGONADISM SUBGROUP. Foundational meta-analytic evidence — most rigorous evidence base for testosterone-supporting herbal supplement.
Erectile function + testosterone in ADAM (6-month RCT)
Henkel et al. (PMID 33541567) — 6-MONTH double-blind placebo-controlled randomized 4-arm clinical trial. Eurycoma longifolia (Tongkat Ali) + CONCURRENT TRAINING in men with ANDROGEN DEFICIENCY OF AGING MALES (ADAM). RESULTS: Combination IMPROVED ERECTILE FUNCTION + INCREASED TOTAL TESTOSTERONE LEVELS in men with ADAM. Testosterone increased in ALMOST 50% of study participants. Important real-world clinical population evidence.
Hypogonadism + LOH testosterone (Tambi 2012)
Tambi 2012 — pre-vs-post study in 76 patients with HYPOGONADISM and LATE-ONSET HYPOGONADISM (LOH). Physta® (Biotropics) — Eurycoma longifolia standardized extract. RESULTS: SIGNIFICANT TESTOSTERONE LEVEL INCREASE in clinically diagnosed hypogonadal patients. Foundational hypogonadism-population evidence supporting clinical translation.
Healthy older volunteers testosterone (50-70 years RCT)
Studies in healthy volunteers aged 50-70 years showed Eurycoma longifolia INCREASES total testosterone vs placebo. Application: aging-related testosterone decline in healthy older men. Subgroup-relevant evidence for age-related applications.
Sedentary young males testosterone (Hamzah 2003)
Trials in sedentary young males (18-30 years) — 600 mg/day for 8 weeks. Testosterone effects documented though baseline testosterone in this group was already adequate. Mixed findings in younger healthy populations vs more compelling effects in hypogonadal/aging populations.
Stress + cortisol reduction (additional indication)
Some Tongkat Ali trials documented STRESS REDUCTION + CORTISOL REDUCTION effects. Mechanism: HPA axis modulation. Important secondary benefit beyond pure androgenic effects. Talbott 2013 reduced cortisol/testosterone ratio in moderately stressed subjects.
Estrogen effects modulation (anti-estrogenic in men)
Eurycomanone shows anti-estrogenic activity in men — inhibits aromatase enzyme converting testosterone to estradiol. Mechanism: maintains testosterone levels by preventing conversion. Important for men where testosterone-to-estrogen conversion contributes to symptoms. Mechanism distinct from direct testosterone biosynthesis.
Mechanism of action
Aromatase inhibition (anti-estrogenic mechanism in men)
Eurycomanone INHIBITS AROMATASE — enzyme converting testosterone to estradiol. Mechanism: maintains testosterone levels in men by preventing conversion to estrogen. Distinct from direct testosterone biosynthesis. Important for aging men where estradiol/testosterone ratio shifts.
Testosterone biosynthesis support
Quassinoids support endogenous testosterone biosynthesis pathways in Leydig cells. Mechanism for testosterone increase in hypogonadal subjects. Distinguishes from synthetic testosterone replacement therapy.
Cortisol/HPA axis modulation
Reduces cortisol levels in stress contexts (Talbott 2013). Mechanism for stress + sleep + recovery benefits. Cortisol-testosterone ratio improvement clinically meaningful.
Quassinoid bioactivity
Eurycomanone is the primary BIOACTIVE QUASSINOID — distinct chemical class from typical herbal flavonoids/alkaloids. Branded extracts standardize to specific eurycomanone percentages for consistent clinical effects.
9-hydroxycanthin-6-one alkaloid bioactivity
Additional alkaloid present in E. longifolia — contributes to bioactive profile complementing eurycomanone. Multi-component bioactive matrix.
SHBG modulation
Some evidence for SHBG (sex hormone binding globulin) modulation — affects free testosterone levels independent of total testosterone. Mechanism for clinical effects beyond raw testosterone increase.
Clinical trials
Systematic review + meta-analysis (Leisegang K, Finelli R, Sikka SC, Panner Selvam MK 2022, Medicina 58(8):1047, doi:10.3390/medicina58081047, PMID 36013514). PMC9415500.
Pooled analysis of E. longifolia clinical trials per PRISMA guidelines. 9 studies in systematic review; 5 RCTs in meta-analysis. Healthy volunteers + hypogonadal men.
SIGNIFICANT INCREASE in TOTAL TESTOSTERONE (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect CONFIRMED in HYPOGONADISM SUBGROUP. Most rigorous evidence base for testosterone-supporting herbal supplement to date. Foundational meta-analytic evidence supporting Tongkat Ali/eurycomanone testosterone claims.
6-month double-blind placebo-controlled randomized 4-arm clinical trial (Henkel et al. 2021, doi:10.1016/j.maturitas.2020.11.012, PMID 33541567).
Men with ADAM (Androgen Deficiency of Aging Males). 4 arms: Eurycoma longifolia + concurrent training, E. longifolia + sedentary, placebo + concurrent training, placebo + sedentary. 6-month intervention.
Eurycoma longifolia + concurrent training IMPROVED ERECTILE FUNCTION + INCREASED TOTAL TESTOSTERONE LEVELS in men with ADAM. Testosterone increased in almost 50% of E. longifolia participants. Concurrent training synergy. Important real-world clinical population (ADAM) evidence with combination intervention.
Pre-vs-post study (Tambi 2012). Biotropics Physta® standardized extract.
76 patients with HYPOGONADISM and LATE-ONSET HYPOGONADISM (LOH). Physta® standardized E. longifolia extract.
SIGNIFICANT TESTOSTERONE LEVEL INCREASE in clinically diagnosed hypogonadal patients. Foundational hypogonadism-population evidence supporting clinical translation of testosterone effects in patients with documented testosterone deficiency. Industry-related context (Biotropics).
About this ingredient
EURYCOMANONE is the PRIMARY BIOACTIVE QUASSINOID compound from EURYCOMA LONGIFOLIA Jack (Tongkat Ali, Long Jack, Pasak Bumi) — Malaysian/Indonesian medicinal plant traditionally used as men's vitality tonic. While the existing Tongkat Ali (LJ100®) entry in NutraSmarts focuses on the branded extract, this entry focuses on EURYCOMANONE specifically as the quassinoid bioactive. Additional bioactives in E. longifolia: 9-hydroxycanthin-6-one (alkaloid), β-anhydroxonoeurycomalactone, eurycolactone, other quassinoids. BRANDED STANDARDIZED EXTRACTS: PHYSTA® (Biotropics Malaysia) and LJ100® standardize to specific eurycomanone percentages (Physta® 0.8-1.5% eurycomanone). PIVOTAL CLINICAL EVIDENCE: LEISEGANG 2022 PMID 36013514 PMC9415500 (Medicina 58(8):1047) SYSTEMATIC REVIEW + META-ANALYSIS per PRISMA guidelines — 9 studies in review, 5 RCTs in meta-analysis. RESULTS: SIGNIFICANT INCREASE in TOTAL TESTOSTERONE (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect CONFIRMED in HYPOGONADISM SUBGROUP. MOST RIGOROUS evidence base for testosterone-supporting herbal supplement to date. HENKEL 2021 PMID 33541567 (Maturitas) — 6-MONTH 4-ARM RCT in ADAM (Androgen Deficiency of Aging Males) men: E. longifolia + concurrent training improved erectile function + testosterone in ~50% of participants. TAMBI 2012 — 76 patients with hypogonadism + LOH at Physta® showed significant testosterone increase. Multiple smaller RCTs in healthy 50-70 year volunteers + sedentary 18-30 year males. TALBOTT 2013 — cortisol/testosterone ratio improvement in moderately stressed subjects.
MECHANISMS: AROMATASE INHIBITION (anti-estrogenic mechanism — eurycomanone inhibits conversion of testosterone to estradiol, distinct from direct testosterone biosynthesis); TESTOSTERONE BIOSYNTHESIS SUPPORT in Leydig cells; CORTISOL/HPA AXIS MODULATION (Talbott 2013 mechanism); QUASSINOID BIOACTIVITY (distinct chemical class); 9-hydroxycanthin-6-one alkaloid additional bioactivity; SHBG modulation affecting free testosterone. EVIDENCE: 3/5 reflects: (1) LEISEGANG 2022 META-ANALYSIS PIVOTAL evidence with statistical significance + hypogonadism subgroup confirmation, (2) HENKEL 2021 6-month ADAM RCT — real-world clinical population, (3) TAMBI 2012 hypogonadism + LOH evidence, (4) MULTIPLE SMALLER RCTs in healthy volunteers + sedentary males, (5) WELL-CHARACTERIZED aromatase inhibition + testosterone biosynthesis mechanisms, (6) STANDARDIZED BRANDED EXTRACTS (Physta® and LJ100®) with consistent eurycomanone content, (7) TALBOTT 2013 cortisol/testosterone ratio evidence (broader application), (8) industry-related research context (Biotropics/Physta®, etc.) — important caveat, (9) META-ANALYTIC EVIDENCE BASE rare among testosterone-supporting herbs. SAFETY: Generally favorable at typical doses; heavy metal contamination historical concern with non-standardized extracts (24/41 Malaysian products in older surveys) makes branded extracts (Physta®, LJ100®) preferable. Best positioned as: (a) HYPOGONADAL MEN testosterone support adjunct (most rigorous evidence per Leisegang 2022 subgroup confirmation), (b) ADAM (androgen deficiency aging males) adjunct + concurrent training combination (Henkel 2021 evidence), (c) AGE-RELATED testosterone decline (limited but supportive evidence), (d) MALE LIBIDO + ED adjunct (combined testosterone + erectile function evidence), (e) STRESS reduction + cortisol/testosterone ratio improvement (Talbott 2013), (f) NOT recommended for PROSTATE CANCER history (hormonal effects), (g) PREGNANCY: AVOID, (h) preferable: STANDARDIZED BRANDED EXTRACTS (Physta®, LJ100®) over non-standardized supplements due to historical contamination concerns + need for consistent eurycomanone content. Honest framing: Eurycomanone/E. longifolia has the MOST RIGOROUS META-ANALYTIC EVIDENCE among testosterone-supporting herbal supplements — Leisegang 2022 systematic review + meta-analysis with statistical significance (SMD 1.352, p=0.001) is genuinely robust evidence base rare for botanicals. Hypogonadism subgroup confirmation important for clinical translation. Henkel 2021 6-month ADAM RCT real-world relevance. Aromatase inhibition mechanism is biochemically distinct from typical testosterone-boosting mechanisms — supports clinical effect plausibility. Industry-related research context (Biotropics, etc.) warrants caveat but methodology consistent across multiple investigators. Heavy metal contamination historical concern argues for STANDARDIZED BRANDED EXTRACTS. Reasonable testosterone support adjunct based on evidence — particularly compelling for men with documented hypogonadism or ADAM seeking herbal alternatives or adjuncts to testosterone replacement therapy.